

development efforts provide tailored resource support to *Senior Legal Helplines* (SLH) and *Model Approaches to Statewide Legal Assistance Systems* (Model Approaches) projects across the country. Model Approaches grants promote the creation of legal services delivery systems that incorporate SLHs (and other low-cost service delivery mechanisms) into the broader tapestry of Title III-B legal services, and other available legal resources. Specifically, the TA grant directed to SLHs provides resource support for various aspects of helpline legal service delivery, including the development of reporting/data collection systems, case management systems, targeting and outreach strategies, and integration strategies that incorporate SLHs into the broader tapestry of legal service delivery in each Model Approaches state. The TA grant directed to the systems enhancement objectives of Model Approaches Phase I and Phase II projects provides resource support on the development of needs and capacity assessments, reporting/data collection systems and outcomes measures used to determine the impact of legal services, and the development of legal service delivery standards/guidelines that promote quality and consistent statewide legal service delivery.

## II. Justification for The Exception to Competition

As with the grants comprising the National Legal Resource Center, it is important to assess the effectiveness of TA grants in helping states meet increasing challenges in the development and maintenance of “high capacity” statewide legal service delivery systems. To this end, ACL would like to accomplish two goals this year: (1) Obtain stakeholder input on the resource support needs of legal and aging/disability service providers across the country and the ability to meet those needs through focused TA grants; and (2) establish how best to direct the current objectives of the TA grants towards advancing anticipated ACL FY 15 activities related to elder rights and elder abuse prevention.

## III. Eligible Applicants

Incumbent TA grantees with award expiration dates of 5/31/14.

## IV. Evaluation Criteria

Information previously provided in semi-annual reports, as well as information in the non-competing extension application will be considered to determine satisfactory progress of the grantee project and ensure that proposed activities are

within the approved scope and budget of the grant. Areas that will be evaluated include:

- A. *Project Relevance & Current Need*
- B. *Approach*
- C. *Budget*
- D. *Project Impact*
- E. *Organizational Capacity*

## V. Application and Submission Requirements

- A. SF 424—Application for Federal Assistance
- B. SF 424A—Budget Information
- C. Separate Budget Narrative/Justification
- D. SF 424B—Assurances. Note: Be sure to complete this form according to instructions and have it signed and dated by the authorized representative (see item 18d of the SF 424).
- E. Lobbying Certification
- F. Program narrative—no more than 10 pages.
- G. Work Plan
- H. Incumbent grantees will be required to access the non-competing application kit in GrantSolutions.gov to submit all materials for this application.

## VI. Application Review Information

Applications will be objectively reviewed by Federal staff utilizing the criteria listed above in Section III.

## VII. Agency Contact

For further information or comments regarding this program expansion supplement, contact Omar Valverde, U.S. Department of Health and Human Services, Administration for Community Living, Administration on Aging, Office of Elder Rights, One Massachusetts Avenue NW., Washington, DC 20001; telephone (202) 357-3515; fax (202) 357-3549; email [omar.valverde@acl.hhs.gov](mailto:omar.valverde@acl.hhs.gov).

Dated: March 27, 2014.

**Kathy Greenlee,**

*Administrator and Assistant Secretary for Aging.*

[FR Doc. 2014-07340 Filed 4-1-14; 8:45 am]

**BILLING CODE 4154-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2013-N-0796]

#### Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Testing Communications on Medical Devices and Radiation-Emitting Products

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled “Testing Communications on Medical Devices and Radiation-Emitting Products” has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

**FOR FURTHER INFORMATION CONTACT:** FDA PRA Staff, Office of Operations, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, [PRASStaff@fda.hhs.gov](mailto:PRASStaff@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** On December 20, 2013, the Agency submitted a proposed collection of information entitled “Testing Communications on Medical Devices and Radiation-Emitting Products” to OMB for review and clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0678. The approval expires on March 31, 2017. A copy of the supporting statement for this information collection is available on the Internet at <http://www.reginfo.gov/public/do/PRAMain>.

Dated: March 27, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014-07325 Filed 4-1-14; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2013-P-1379]

#### Determination That PREZISTA (Darunavir) Tablets, 400 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or the Agency) has determined that PREZISTA (darunavir) tablets, 400 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for darunavir tablets, 400 mg, if all other legal and regulatory requirements are met.